bluuebunny/crossref_metadata_2025 huggingface dataset:
Adobe PDF - MCT-13-0925_fig_leg_fig_1_to_7.pdf from BET Bromodomain Inhibitors Block Growth of Pancreatic Cancer Cells in Three-Dimensional Collagen
Authors: Sahai Vaibhav , Kumar Krishan , Knab Lawrence M. , Chow Christina R. , Raza Sania S. , Bentrem David J. , Ebine Kazumi , Munshi Hidayatullah G.
Published: April 2023

PDF - 1346K, Fig. S1: Effect of I-BET151 on PDAC cells. Figs. S2 and S3: Effect of I-BET on Snail-expressing PDAC cells. Fig. S4: Effect of I-BET151 on chemo-resistant cells. Figs. S5 and S6: Effect of I-BET151 on c-MYC and FOSL1. Fig. S7: ChIP results.
Supplementary Figure 2 from Elevated Cyclin D1 Expression Is Predictive for a Benefit from TPF Induction Chemotherapy in Oral Squamous Cell Carcinoma Patients with Advanced Nodal Disease
Authors: Zhong Lai-Ping , Zhu Dong-Wang , William William N. , Liu Ying , Ma Jie , Yang Cheng-Zhe , Yang Xiao , Wang Li-Zhen , Li Jiang , Myers Jeffrey N. , Lee J. Jack , Zhang Chen-Ping , Zhang Zhi-Yuan
Published: April 2023

PDF file - 746K, Forest plot of overall survival, disease-free survival, locoregional recurrence-free survival, and distant metastasis-free survival in OSCC patients treated with surgery and post-operative radiotherapy with and without TPF induction chemotherapy.
Supplementary Figure Legends from Bone Marrow–Derived Mesenchymal Stromal Cells Promote Survival and Drug Resistance in Tumor Cells
Authors: Bergfeld Scott A. , Blavier Laurence , DeClerck Yves A.
Published: April 2023

PDF - 61K, Legends to supplementary figures 1, 2, and 3.
Supplementary Figure 5 from Combination of Anti-HER3 Antibody MM-121/SAR256212 and Cetuximab Inhibits Tumor Growth in Preclinical Models of Head and Neck Squamous Cell Carcinoma
Authors: Jiang Ning , Wang Dongsheng , Hu Zhongliang , Shin Hyung Ju C. , Qian Guoqing , Rahman Mohammad Aminur , Zhang Hongzheng , Amin A.R.M. Ruhul , Nannapaneni Sreenivas , Wang Xiaojing , Chen Zhengjia , Garcia Gabriela , MacBeath Gavin , Shin Dong M. , Khuri Fadlo R. , Ma Jun , Chen Zhuo G. , Saba Nabil F.
Published: April 2023

PDF file - 74KB, The body weight changes in mice during treatment.
Supplementary figure S4 from Mechanisms of Overcoming Intrinsic Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma through the Redox Modulation
Authors: Ju Huai-Qiang , Gocho Takeshi , Aguilar Mitzi , Wu Min , Zhuang Zhuo-Nan , Fu Jie , Yanaga Katsuhiko , Huang Peng , Chiao Paul J.
Published: April 2023

Supplementary figure S4. BSO showed similar effects as PEITC and GME rescued PEITC-induced apoptosis in MIAPaCa-2 cells.
Supplementary Figure S2 from The TMPRSS2–ERG Gene Fusion Blocks XRCC4-Mediated Nonhomologous End-Joining Repair and Radiosensitizes Prostate Cancer Cells to PARP Inhibition
Authors: Chatterjee Payel , Choudhary Gaurav S. , Alswillah Turkeyah , Xiong Xiahui , Heston Warren D. , Magi-Galluzzi Cristina , Zhang Junran , Klein Eric A. , Almasan Alexandru
Published: April 2023

TMPRSS2/ERG expression reduces S964 MDC-1 but not S25 53BP1 IRIFs. Confocal immunostaining for phosphorylation of S25-53BP1 (A) and S964-MDC1 (B) in PC3 and TMPRSS2-ERG-expressing cells at the indicated times after IR. Right panel indicates the quantified foci/nucleus. Error bars represent SD (n=3).
Supplementary Table 1 from NSCLC Driven by DDR2 Mutation Is Sensitive to Dasatinib and JQ1 Combination Therapy
Authors: Xu Chunxiao , Buczkowski Kevin A. , Zhang Yanxi , Asahina Hajime , Beauchamp Ellen M. , Terai Hideki , Li Yvonne Y. , Meyerson Matthew , Wong Kwok-kin , Hammerman Peter S.
Published: April 2023

microarray gene expression data with q value (FDR corrected p value)
Supplementary Figure Legends from A Chemically Defined Trifunctional Antibody–Cytokine–Drug Conjugate with Potent Antitumor Activity
Authors: List Thomas , Casi Giulio , Neri Dario
Published: April 2023

Legends for Supplementary Figures S1, S2, and S3.
Data Supplement from Pharmacogenetic Predictors of Outcome in Patients with Stage II and III Colon Cancer Treated with Oxaliplatin and Fluoropyrimidine-Based Adjuvant Chemotherapy
Authors: Custodio Ana , Moreno-Rubio Juan , Aparicio Jorge , Gallego-Plazas Javier , Yaya Ricardo , Maurel Joan , Rodríguez-Salas Nuria , Burgos Emilio , Ramos David , Calatrava Ana , Andrada Encarna , Díaz-López Esther , Sánchez Antonio , Madero Rosario , Cejas Paloma , Feliu Jaime
Published: April 2023

Supplementary Table S4. Cox regression multivariate analysis for disease free survival (DFS) in female patients.
Figure S4 from Radiotherapy Followed by Aurora Kinase Inhibition Targets Tumor-Propagating Cells in Human Glioblastoma
Authors: Li Nan , Maly Dustin J. , Chanthery Yvan H. , Sirkis Daniel W. , Nakamura Jean L. , Berger Mitchel S. , James C. David , Shokat Kevan M. , Weiss William A. , Persson Anders I.
Published: April 2023

Figure S4. Sequential treatment with radiotherapy and the pan-AURK inhibitor VX680 to target TPCs in human primary GBM43 cultures.
Supplementary Tables and Figures from Targeting Three Distinct HER2 Domains with a Recombinant Antibody Mixture Overcomes Trastuzumab Resistance
Authors: Pedersen Mikkel W. , Jacobsen Helle J. , Koefoed Klaus , Dahlman Anna , Kjær Ida , Poulsen Thomas T. , Meijer Per-Johan , Nielsen Lars S. , Horak Ivan D. , Lantto Johan , Kragh Michael
Published: April 2023

Supplementary Tables and Figures. Table S1 contains affinities for antibodies binding to HER2. Table S2 contains results from epitope bin analysis of the antibodies. Figure S1 shows a comparison of Perjeta and the pertuzumab analogue used in this paper. Figure S2 shows sensograms for the anti-HER2 antibodies. Figure S3 contains dose-response curves for anti-HER2 lead mixtures in the cell lines BT474, SK-BR3, HCC202 and NCI-N87. Figure S4 shows immunoblot data on the levels of HER2, pHER2, EGFR, pEGFR, HER3 and pHER3 in the eight cell lines OE19, N87, MCF7, MDA-MB-175, BT474, HCC202 SK-BR3 and ZE-75-30. Figure S5 shows activity of anti-HER2 mAbs and mixtures in ADCC and CDC assays. Figure S6 demonstrates synergy of the tripartite mixture in OE19 cell line. Figure S7 shows quantification of HER2 and pHER2 levels in OE19 and HCC202 cell lines upon treatment with anti-HER2 mAbs and mixtures. Figure S8 shows activity of tripartite mixtures of trastuzumab, pertuzumab and lead anti-HER2 antibodies in a cell viability assay
Supplementary Figure S6 from Glycogen Synthase Kinase 3β Sustains Invasion of Glioblastoma via the Focal Adhesion Kinase, Rac1, and c-Jun N-Terminal Kinase-Mediated Pathway
Authors: Chikano Yuri , Domoto Takahiro , Furuta Takuya , Sabit Hemragul , Kitano-Tamura Ayako , Pyko Ilya V. , Takino Takahisa , Sai Yoshimichi , Hayashi Yutaka , Sato Hiroshi , Miyamoto Ken-ichi , Nakada Mitsutoshi , Minamoto Toshinari
Published: April 2023

Effect of GSK3beta inhibition on phosphorylation of glycogen synthase in a mouse model of glioblastoma.
SupMovie1b from TRX-E-002-1 Induces c-Jun–Dependent Apoptosis in Ovarian Cancer Stem Cells and Prevents Recurrence In Vivo
Authors: Alvero Ayesha B. , Heaton Andrew , Lima Eydis , Pitruzzello Mary , Sumi Natalia , Yang-Hartwich Yang , Cardenas Carlos , Steinmacher Sahra , Silasi Dan-Arin , Brown David , Mor Gil
Published: April 2023

Cells treated with vehicle control
Supplementary File 4_Reactome Pathway Analysis from Pathway-Enriched Gene Signature Associated with 53BP1 Response to PARP Inhibition in Triple-Negative Breast Cancer
Authors: Hassan Saima , Esch Amanda , Liby Tiera , Gray Joe W. , Heiser Laura M.
Published: April 2023

Enriched pathways derived from Reactome Pathway Analysis.
Supplementary Table and Supplementary Figures 1-2 from The Irreversible Covalent Fibroblast Growth Factor Receptor Inhibitor PRN1371 Exhibits Sustained Inhibition of FGFR after Drug Clearance
Authors: Venetsanakos Eleni , Brameld Ken A. , Phan Vernon T. , Verner Erik , Owens Timothy D. , Xing Yan , Tam Danny , LaStant Jacob , Leung Kwan , Karr Dane E. , Hill Ronald J. , Gerritsen Mary E. , Goldstein David M. , Funk Jens Oliver , Bradshaw J. Michael
Published: April 2023

Supplementary Table S1. Percentage of enzyme activity following dialysis compared to a non-compound treated control; Supplementary Figure S1. PRN1371 inhibited SNU16 cell proliferation as assessed by BrdU incorporation; Supplementary Figure S2. PRN1371 treatment induces apoptosis via caspase activation.
Table S5 from Receptor Tyrosine Kinase Phosphorylation Pattern–Based Multidrug Combination Is an Effective Approach for Personalized Cancer Treatment
Authors: Sun Xiaoxiao , Song Qiaoling , He Li , Yan Lei , Liu Jingli , Zhang Qing , Yu Qiang
Published: April 2023

Drug effects on the viabilities of SMMC7721 cells.
Supplementary Figure S9 from Preclinical Antitumor Efficacy of BAY 1129980—a Novel Auristatin-Based Anti-C4.4A (LYPD3) Antibody–Drug Conjugate for the Treatment of Non–Small Cell Lung Cancer
Authors: Willuda Jörg , Linden Lars , Lerchen Hans-Georg , Kopitz Charlotte , Stelte-Ludwig Beatrix , Pena Carol , Lange Claudia , Golfier Sven , Kneip Christoph , Carrigan Patricia E. , Mclean Kirk , Schuhmacher Joachim , von Ahsen Oliver , Müller Jörg , Dittmer Frank , Beier Rudolf , El Sheikh Sherif , Tebbe Jan , Leder Gabriele , Apeler Heiner , Jautelat Rolf , Ziegelbauer Karl , Kreft Bertolt
Published: April 2023

Changes in the relative sizes of NCI-H322 tumors (A), SCC-4 tumors (B), SCaBER tumors (C), FaDu tumors (D), Lu7064 tumors (E) Lu7126 tumors (F), Lu7343 tumors (G), Lu7433 tumors (H), Lu7466 tumors (I), and Lu7700 tumors (J).
Supplementary Figure S8 from Preclinical Antitumor Efficacy of BAY 1129980—a Novel Auristatin-Based Anti-C4.4A (LYPD3) Antibody–Drug Conjugate for the Treatment of Non–Small Cell Lung Cancer
Authors: Willuda Jörg , Linden Lars , Lerchen Hans-Georg , Kopitz Charlotte , Stelte-Ludwig Beatrix , Pena Carol , Lange Claudia , Golfier Sven , Kneip Christoph , Carrigan Patricia E. , Mclean Kirk , Schuhmacher Joachim , von Ahsen Oliver , Müller Jörg , Dittmer Frank , Beier Rudolf , El Sheikh Sherif , Tebbe Jan , Leder Gabriele , Apeler Heiner , Jautelat Rolf , Ziegelbauer Karl , Kreft Bertolt
Published: April 2023

Anti-tumor efficacy of C4.4A-Ab and C4.4A-ADC in NCI-H292 human NSCLC xenograft mouse model.
Supplementary Figure 3 from ML264, A Novel Small-Molecule Compound That Potently Inhibits Growth of Colorectal Cancer
Authors: Ruiz de Sabando Ainara , Wang Chao , He Yuanjun , García-Barros Mónica , Kim Julie , Shroyer Kenneth R. , Bannister Thomas D. , Yang Vincent W. , Bialkowska Agnieszka B.
Published: April 2023

ML264 treatment decreases EGR1 expression levels in DLD-1-derived xenografts.
Supplemental Figure 6 from Antitumor Activity of Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor, in ETV6-NTRK3–Positive Acute Myeloid Leukemia
Authors: Smith Kristen M. , Fagan Patrick C. , Pomari Elena , Germano Giuseppe , Frasson Chiara , Walsh Colin , Silverman Ian , Bonvini Paolo , Li Gang
Published: April 2023

Entrectinib was not toxic in zebrafish xenograft assay.
Supplemental Figure 4 from Antitumor Activity of Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor, in ETV6-NTRK3–Positive Acute Myeloid Leukemia
Authors: Smith Kristen M. , Fagan Patrick C. , Pomari Elena , Germano Giuseppe , Frasson Chiara , Walsh Colin , Silverman Ian , Bonvini Paolo , Li Gang
Published: April 2023

Entrectinib treatment does not result in body weight loss.
Supplemental Figure 3 from Antitumor Activity of Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor, in ETV6-NTRK3–Positive Acute Myeloid Leukemia
Authors: Smith Kristen M. , Fagan Patrick C. , Pomari Elena , Germano Giuseppe , Frasson Chiara , Walsh Colin , Silverman Ian , Bonvini Paolo , Li Gang
Published: April 2023

Entrectinib treatment rapidly induces apoptosis in ETV6-NTRK3-driven AML cell lines.
Supplementary Table I from HMG-CoA Reductase Inhibition Delays DNA Repair and Promotes Senescence After Tumor Irradiation
Authors: Efimova Elena V. , Ricco Natalia , Labay Edwardine , Mauceri Helena J. , Flor Amy C. , Ramamurthy Aishwarya , Sutton Harold G. , Weichselbaum Ralph R. , Kron Stephen J.
Published: April 2023

Supplementary Table 1. shRNAs used
Supplement Figure 3 from Auranofin Enhances Ibrutinib's Anticancer Activity in EGFR-Mutant Lung Adenocarcinoma
Authors: Hu Jing , Zhang Huijuan , Cao Mengru , Wang Li , Wu Shuhong , Fang Bingliang
Published: April 2023

Relative value of phosphor-AKT, mTOR, 70S6K, MEK and ERK based on intensity of Western blot bands of Figure 4. Up panel: H1975; low panel: H1650. The value was determined using software ImageJ and normalized with β-actin.
Table S1 and S2 from HIF2α-Targeted RNAi Therapeutic Inhibits Clear Cell Renal Cell Carcinoma
Authors: Wong So C. , Cheng Weijun , Hamilton Holly , Nicholas Anthony L. , Wakefield Darren H. , Almeida Aaron , Blokhin Andrei V. , Carlson Jeffrey , Neal Zane C. , Subbotin Vladimir , Zhang Guofeng , Hegge Julia , Bertin Stephanie , Trubetskoy Vladimir S. , Rozema David B. , Lewis David L. , Kanner Steven B.
Published: April 2023

DPC characteristics and Clinical chemistry
Figure S3 from Monitoring Tumor Burden in Response to FOLFIRINOX Chemotherapy Via Profiling Circulating Cell-Free DNA in Pancreatic Cancer
Authors: Wei Tao , Zhang Qi , Li Xiang , Su Wei , Li Guogang , Ma Tao , Gao Shunliang , Lou Jianying , Que Risheng , Zheng Lei , Bai Xueli , Liang Tingbo
Published: April 2023

The comparison of overall survival in patients with ctDNA MAF over or below 1.5%.
Supplemental Figure 2 from Arginine Deprivation Therapy: Putative Strategy to Eradicate Glioblastoma Cells by Radiosensitization
Authors: Hinrichs C. Noreen , Ingargiola Mirjam , Käubler Theresa , Löck Steffen , Temme Achim , Köhn-Luque Alvaro , Deutsch Andreas , Vovk Olena , Stasyk Oleh , Kunz-Schughart Leoni A.
Published: April 2023

Suppl. Figs. 2A/B show representative flow cytometric histograms and dot blot diagrams to support the finding that (i) ADT leads to cell cycle arrest in all GBM 2-D cultures and that (ii) arginine-equimolar citrulline does compensate this effect.
Tables S1, S2, S3 from Inhibition of Parp1 by BMN673 Effectively Sensitizes Cells to Radiotherapy by Upsetting the Balance of Repair Pathways Processing DNA Double-Strand Breaks
Authors: Soni Aashish , Li Fanghua , Wang You , Grabos Martha , Krieger Lisa Marie , Chaudhary Shipra , Hasan Mohammad Sharif Mortoga , Ahmed Mansoor , Coleman C. Norman , Teicher Beverly A. , Piekarz Richard L. , Wang Dian , Iliakis George E.
Published: April 2023

Table S1: Dose Modification Factor at 10% survival in different cell lines. Table S2: List of primary and secondary antibodies. Table S3: Cytotoxicity of different inhibitors in un-irradiated CHO cells.
Figure S3 from TAS-114, a First-in-Class Dual dUTPase/DPD Inhibitor, Demonstrates Potential to Improve Therapeutic Efficacy of Fluoropyrimidine-Based Chemotherapy
Authors: Yano Wakako , Yokogawa Tatsushi , Wakasa Takeshi , Yamamura Keisuke , Fujioka Akio , Yoshisue Kunihiro , Matsushima Eiji , Miyahara Seiji , Miyakoshi Hitoshi , Taguchi Junko , Chong Khoon Tee , Takao Yayoi , Fukuoka Masayoshi , Matsuo Kenichi
Published: April 2023

TAS-114 possesses moderate DPD inhibitory activity, and its inhibition mode is reversible
Figure S1 from TAS-114, a First-in-Class Dual dUTPase/DPD Inhibitor, Demonstrates Potential to Improve Therapeutic Efficacy of Fluoropyrimidine-Based Chemotherapy
Authors: Yano Wakako , Yokogawa Tatsushi , Wakasa Takeshi , Yamamura Keisuke , Fujioka Akio , Yoshisue Kunihiro , Matsushima Eiji , Miyahara Seiji , Miyakoshi Hitoshi , Taguchi Junko , Chong Khoon Tee , Takao Yayoi , Fukuoka Masayoshi , Matsuo Kenichi
Published: April 2023

Detail description of TAS-114 synthesis
Figure S6 from Inhibition of FLT3 and PIM Kinases by EC-70124 Exerts Potent Activity in Preclinical Models of Acute Myeloid Leukemia
Authors: Puente-Moncada Noelia , Costales Paula , Antolín Isaac , Núñez Luz-Elena , Oro Patricia , Hermosilla Maria Ana , Pérez-Escuredo Jhudit , Ríos-Lombardía Nicolás , Sanchez-Sanchez Ana M. , Luño Elisa , Rodríguez Carmen , Martín Vanesa , Morís Francisco
Published: April 2023

Kaplan-Meier plots
Supplementary Figure S1 from Targeting MEK in a Translational Model of Histiocytic Sarcoma
Authors: Takada Marilia , Hix Jeremy M.L. , Corner Sarah , Schall Peter Z. , Kiupel Matti , Yuzbasiyan-Gurkan Vilma
Published: April 2023

Immunohistochemical characterization of HS cell lines CD204 and CD18 are standard cell surface markers expressed by HS in dogs. Newly established HS cell lines were positive with both CD204 and CD18 by IHC of sections of cell pellets. CD3 and CD79a were used to rule out a lymphoid phenotype, for which all cell lines were negative. Calibration bar: 100 μm.
Supplementary Tables S1-S5 and Figures S1-S4 from ABT-165, a Dual Variable Domain Immunoglobulin (DVD-Ig) Targeting DLL4 and VEGF, Demonstrates Superior Efficacy and Favorable Safety Profiles in Preclinical Models
Authors: Li Yingchun , Hickson Jonathan A. , Ambrosi Dominic J. , Haasch Deanna L. , Foster-Duke Kelly D. , Eaton Lucia J. , DiGiammarino Enrico L. , Panchal Sanjay C. , Jiang Fang , Mudd Sarah R. , Zhang Catherine , Akella Surekha S. , Gao Wenqing , Ralston Sherry L. , Naumovski Louie , Gu Jijie , Morgan-Lappe Susan E.
Published: April 2023

Table S1: ABT-165 binding affinity; Table S2: ABT-165 in vitro potency; Table S3: Effect of VEGF on anti-DLL4 cellular potency of ABT-165; Table S4: Summary of in vivo efficacy; Table S5: Key safety findings of ABT-487 and ABT-165; Figure S1: Serum concentration-time profiles of ABT-165 in cynomolgus monkeys; Figure S2: Effect of antibody or antibody fragment valency on anti-DLL4 cellular potency; Figure S3: Effect of VEGF on the activity of DLL4 mAb and ABT-165 to downregulate DLL4 protein; Figure S4: Plasma levels of total soluble DLL4 and VEGF in cynomolgus monkeys after ABT-165 treatment.
Supplementary Table S3 from Nuclear Factor-κB Promotes Urothelial Tumorigenesis and Cancer Progression via Cooperation with Androgen Receptor Signaling
Authors: Inoue Satoshi , Ide Hiroki , Mizushima Taichi , Jiang Guiyang , Netto George J. , Gotoh Momokazu , Miyamoto Hiroshi
Published: April 2023

Correlation between NF-κB/p-NF-κB expression and clinicopathological profile of the patients.
Supplementary Figures from PLK1 Inhibition Targets Myc-Activated Malignant Glioma Cells Irrespective of Mismatch Repair Deficiency–Mediated Acquired Resistance to Temozolomide
Authors: Higuchi Fumi , Fink Alexandria L. , Kiyokawa Juri , Miller Julie J. , Koerner Mara V.A. , Cahill Daniel P. , Wakimoto Hiroaki
Published: April 2023

Figure S1. A compound screen identifies Volasertib as potently cytotoxic to MSH6-deficient glioblastoma cells. Figure S2. The effects of temozolomide and PLK1 inhibitors on glioblastoma cells with and without MSH6 knockdown. Figure S3. Combination of Volasertib and temozolomide on glioblastoma cells with and without MSH6 knockdown. Figure S4. PLK1 inhibitor effects in orthotopic glioblastoma models. Figure S5. In vitro PLK1 inhibitor effects on normal astrocytes and glioblastoma cells. Figure S6. Myc expression and PLK1 inhibitor effects.
Supplementary Table S1 and Figures S1-S7 from ODM-203, a Selective Inhibitor of FGFR and VEGFR, Shows Strong Antitumor Activity, and Induces Antitumor Immunity
Authors: Holmström Tim H. , Moilanen Anu-Maarit , Ikonen Tarja , Björkman Mari L. , Linnanen Tero , Wohlfahrt Gerd , Karlsson Stefan , Oksala Riikka , Korjamo Timo , Samajdar Susanta , Rajagopalan Srinivasan , Chelur Shekar , Narayanan Kishore , Ramachandra Raghuveer K. , Mani Jiju , Nair Rashmi , Gowda Nagaraj , Anthony Thomas , Dhodheri Samiulla , Mukherjee Subhendu , Ujjinamatada Ravi K. , Srinivas Nanduri , Ramachandra Murali , Kallio Pekka J.
Published: April 2023

Supplementary table S1 shows the effect of ODM-203 in a large kinase panel. Supplementary figure S1 shows how ODM-203 is synthesized. Supplementary figure S2 shows the effect of ODM-203 on FRS2 phosphorylation. Supplement figure S3 shows the effect of ODM-203 in additional in vivo xenograft models. Supplement figure S4 shows the effect of ODM-203 on pFGFR in the SNU16 xenograft model. Supplement figure S5 shows the effect of ODM-203 on pFGFR in the KSM11 xenograft model. Supplement figure S6 shows the effect of ODM-203 angiogenesis in vivo. Supplement figure S7 shows the effect of ODM-203 on PD-L1 expression in vitro.
Figure S3 from Acquired JHDM1D–BRAF Fusion Confers Resistance to FGFR Inhibition in FGFR2-Amplified Gastric Cancer
Authors: Sase Hitoshi , Nakanishi Yoshito , Aida Satoshi , Horiguchi-Takei Kana , Akiyama Nukinori , Fujii Toshihiko , Sakata Kiyoaki , Mio Toshiyuki , Aoki Masahiro , Ishii Nobuya
Published: April 2023

Screening for point mutations in major oncogenes.
Supplementary Tables S1-S5 from Combinatorial Therapy of Zinc Metallochaperones with Mutant p53 Reactivation and Diminished Copper Binding
Authors: Zaman Saif , Yu Xin , Bencivenga Anthony F. , Blanden Adam R. , Liu Yue , Withers Tracy , Na Bing , Blayney Alan J. , Gilleran John , Boothman David A. , Loh Stewart N. , Kimball S. David , Carpizo Darren R.
Published: April 2023

Supplementary tables to show combination index values for combination treatments of indicated compounds. Supplementary Table 1. Combination Index values for initial combination treatment of ZMC1 with chemotherapy drugs; Supplementary Table 2. Combination Index values for combination treatment of ZMC1 with chemotherapy drugs in the presence of GSH; Supplementary Table 3. Combination Index values for combination treatment of ZMC1 with Irinotecan with or without GSH in Detroit 562 cells; Supplementary Table 4. Combination Index values for combination treatment of MEE or DEE with Etoposide; Supplementary Table 5. Combination Index values for combination treatment of ZMC1 with the indicated compounds
Supplementary Data from Neuregulin Signaling Is a Mechanism of Therapeutic Resistance in Head and Neck Squamous Cell Carcinoma
Authors: Baro Marta , Lopez Sambrooks Cecilia , Burtness Barbara A. , Lemmon Mark A. , Contessa Joseph N.
Published: April 2023

Supplementary Figure S1, Supplementary Figure S2 and Supplementary Table 1
Table S1 from Monoclonal Antibody Targeting Sialyl-di-Lewisa–Containing Internalizing and Noninternalizing Glycoproteins with Cancer Immunotherapy Development Potential
Authors: Tivadar Silvana T. , McIntosh Richard S. , Chua Jia Xin , Moss Robert , Parsons Tina , Zaitoun Abed M. , Madhusudan Srinivasan , Durrant Lindy G. , Vankemmelbeke Mireille
Published: April 2023

DAR values for ADC conjugates
Figure S2 from Monoclonal Antibody Targeting Sialyl-di-Lewisa–Containing Internalizing and Noninternalizing Glycoproteins with Cancer Immunotherapy Development Potential
Authors: Tivadar Silvana T. , McIntosh Richard S. , Chua Jia Xin , Moss Robert , Parsons Tina , Zaitoun Abed M. , Madhusudan Srinivasan , Durrant Lindy G. , Vankemmelbeke Mireille
Published: April 2023

FG129 and CH129 target their glyco-epitope in vitro with nanomolar functional affinity
Supplemental figure legends from Antitumor Effects of MEHD7945A, a Dual-Specific Antibody against EGFR and HER3, in Combination with Radiation in Lung and Head and Neck Cancers
Authors: Li Chunrong , Huang Shyhmin , Armstrong Eric A. , Francis David M. , Werner Lauryn R. , Sliwkowski Mark X. , van der Kogel Albert , Harari Paul M.
Published: April 2023

Supplemental figure legends
Supplementary Figure S1 from Expression of Genes Involved in Vascular Morphogenesis and Maturation Predicts Efficacy of Bevacizumab-Based Chemotherapy in Patients Undergoing Liver Resection
Authors: Stremitzer Stefan , Zhang Wu , Yang Dongyun , Ning Yan , Sunakawa Yu , Matsusaka Satoshi , Parekh Anish , Okazaki Satoshi , Hanna Diana , Astrow Stephanie H. , Moran Miriana , Hernandez Jose , Stephens Craig , Scherer Stefan J. , Stift Judith , Wrba Friedrich , Gruenberger Thomas , Lenz Heinz-Josef
Published: April 2023

Kaplan Meier curves for VEGFB mRNA levels in CLM for RFS (complete response, CR; not reached, NR)
Supplemental figure 4 from Met Signaling Cascade Is Amplified by the Recruitment of Phosphorylated Met to Lipid Rafts via CD24 and Leads to Drug Resistance in Endometrial Cancer Cell Lines
Authors: Ono Yoshihiro Joshua , Tanabe Akiko , Tanaka Tomohito , Tanaka Yoshimichi , Hayashi Masami , Terai Yoshito , Ohmichi Masahide
Published: April 2023

Integrated densities across fractions
Supplementary Table S3A: Mutations by Gene from Genomic and Immunological Tumor Profiling Identifies Targetable Pathways and Extensive CD8+/PDL1+ Immune Infiltration in Inflammatory Breast Cancer Tumors
Authors: Hamm Christopher A. , Moran Diarmuid , Rao Kakuturu , Trusk Patricia B. , Pry Karen , Sausen Mark , Jones Siân , Velculescu Victor E. , Cristofanilli Massimo , Bacus Sarah
Published: April 2023

Gene mutation summary.
Supplemental data from A Potential Mechanism for ADC-Induced Neutropenia: Role of Neutrophils in Their Own Demise
Authors: Zhao Hui , Gulesserian Sara , Malinao Maria Christina , Ganesan Sathish Kumar , Song James , Chang Mi Sook , Williams Melissa M. , Zeng Zhilan , Mattie Michael , Mendelsohn Brian A. , Stover David R. , Doñate Fernando
Published: April 2023

Figure S1. Chemical structures of MMAF, MMAE and 13C5-MMAE. The asterisks indicate where Carbon-13 isotope has replaced Carbon-12; Figure S2. Expression of CD32 on mature neutrophils. Circulating neutrophils (AllCell) were incubated with anti-CD32 antibody conjugated with FITC (CD32-FITC) or control IgG1-FITC, and were subjected to FACS analysis. Typical results from one experiment were shown; Figure S3. Little expression of SLC44A4 and ENPP3 on neutrophils at different differentiation stages. Microarray analyses were done for SLC44A4 (AGS5 target) or ENPP3 (AGS16 target) in HSCs, differentiating neutrophils at Day 8 or Day 14, or circulating neutrophils (mature); Figure S4. AGS5-vcMMAF conjugation did not affect intracellular cleavage. PC3 cells overexpressing SLC44A4, PC3-SLC44A4 were incubated with indicated concentrations of AGS5-vcMMAE, AGS5-vcMMAF or AGS5-mcMMAF for 6 days; Table S1: Information about ADCs used in this report; Table S2: Chromatographic gradient; Table S3: MRM Transitions monitored; Table S4. CD66b expression during neutrophil differentiation; Table S5. Correlation between sensitivity and extracellular cleavage.
Supplemental Figure 1 from Pharmacological Inhibition of Myocardin-related Transcription Factor Pathway Blocks Lung Metastases of RhoC-Overexpressing Melanoma
Authors: Haak Andrew J. , Appleton Kathryn M. , Lisabeth Erika M. , Misek Sean A. , Ji Yajing , Wade Susan M. , Bell Jessica L. , Rockwell Cheryl E. , Airik Merlin , Krook Melanie A. , Larsen Scott D. , Verhaegen Monique , Lawlor Elizabeth R. , Neubig Richard R.
Published: April 2023

The Cancer Genome Atlas (TCGA) cutaneous melanoma dataset was stratified into quartiles based upon expression of indicated genes. Kaplan-Meier plots were generated from the highest (grey) and lowest (black) expressing quartiles. Survival curves were analyzed with the log-rank test with a cutoff of P < 0.05 as statistically significant.
Supplemental Figure 3: UAB30 decreased proliferation. from Preclinical Evaluation of UAB30 in Pediatric Renal and Hepatic Malignancies
Authors: Waters Alicia M. , Stewart Jerry E. , Atigadda Venkatram R. , Mroczek-Musulman Elizabeth , Muccio Donald D. , Grubbs Clinton J. , Beierle Elizabeth A.
Published: April 2023

Cellular proliferation was measured with trypan blue exclusion. Cell lines were treated with UAB30 at 0 or 10 μM for 24 hrs. Cells were stained with trypan blue and counted with a hemacytometer. A The total number of cells decreased in all 3 cell lines, but this decrease did not reach statistical significance. B However, when the ratio between the dead : viable cells was examined, this ratio was significantly increased indicating that the cells were not proliferating.
Legends for supplemental data from Preclinical Evaluation of UAB30 in Pediatric Renal and Hepatic Malignancies
Authors: Waters Alicia M. , Stewart Jerry E. , Atigadda Venkatram R. , Mroczek-Musulman Elizabeth , Muccio Donald D. , Grubbs Clinton J. , Beierle Elizabeth A.
Published: April 2023

Legends for the supplemental figures
Supplementary Material, Text for publication from 15α-methoxypuupehenol Induces Antitumor Effects In Vitro and In Vivo against Human Glioblastoma and Breast Cancer Models
Authors: Hilliard Tyvette S. , Miklossy Gabriella , Chock Christopher , Yue Peibin , Williams Philip , Turkson James
Published: April 2023

Supplementary text for publication
Supplementary Information from Cotargeting of MEK and PDGFR/STAT3 Pathways to Treat Pancreatic Ductal Adenocarcinoma
Authors: Sahu Nisebita , Chan Emily , Chu Felix , Pham Thinh , Koeppen Hartmut , Forrest William , Merchant Mark , Settleman Jeff
Published: April 2023

Supplementary Figure S1. KP4-derived 3D spheroids with histopathological characteristics of micrometastases show differential sensitivity to small molecule inhibitors; Supplementary Figure S2. Cobimetinib/ponatinib co-treatment increases death of pancreatic cancer cells; Supplementary Figure S3. Cobimetinib/ponatinib co-treatment impairs tumor growth in KPP xenografts; Supplementary Table S1. List of small molecule inhibitors used in drug screen; Supplementary Table S2. Genotype with key mutations of cell lines used in this study; Supplementary Table S3. Tumor growth inhibition (%TGI) of KP4 and KPP xenografts; Supplementary Table S4. TCGA microarray data for normal and PDAC tissues
Supplementary figure legends from Alkylating Agent–Induced NRF2 Blocks Endoplasmic Reticulum Stress–Mediated Apoptosis via Control of Glutathione Pools and Protein Thiol Homeostasis
Authors: Zanotto-Filho Alfeu , Masamsetti V. Pragathi , Loranc Eva , Tonapi Sonal S. , Gorthi Aparna , Bernard Xavier , Gonçalves Rosângela Mayer , Moreira José C.F. , Chen Yidong , Bishop Alexander J.R.
Published: April 2023

Supplementary figure legends for figures S1 to S5.
Supplementary Figure S3 from β-Catenin Inhibitor BC2059 Is Efficacious as Monotherapy or in Combination with Proteasome Inhibitor Bortezomib in Multiple Myeloma
Authors: Savvidou Ioanna , Khong Tiffany , Cuddihy Andrew , McLean Catriona , Horrigan Stephen , Spencer Andrew
Published: April 2023

In vivo effect of BC2059 in gastrointestinal mucosa.
Figure S6 from Acquired Resistance Mechanisms to Combination Met-TKI/EGFR-TKI Exposure in Met-Amplified EGFR-TKI–Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation
Authors: Yamaoka Toshimitsu , Ohmori Tohru , Ohba Motoi , Arata Satoru , Kishino Yasunari , Murata Yasunori , Kusumoto Sojiro , Ishida Hiroo , Shirai Takao , Hirose Takashi , Ohnishi Tsukasa , Sasaki Yasutsuna
Published: April 2023

HSP90 activity maintains the expression of Met through protection from CBL-degradation and transcriptional regulation via SMYD3 in DR6 but not in MET1000 cells.
Figure S5 from Insulin-Mediated Signaling Facilitates Resistance to PDGFR Inhibition in Proneural hPDGFB-Driven Gliomas
Authors: Almiron Bonnin Damian A. , Ran Cong , Havrda Matthew C. , Liu Huan , Hitoshi Yasuyuki , Zhang Zhonghua , Cheng Chao , Ung Matthew , Israel Mark A.
Published: April 2023

Effect of IR inhibition by siRNA knockdown on the cell growth of doxycycline-sensitive and resistant cultures.
Figure S4 from Combined Inhibition of NEDD8-Activating Enzyme and mTOR Suppresses NF2 Loss–Driven Tumorigenesis
Authors: Cooper Jonathan , Xu Qingwen , Zhou Lu , Pavlovic Milica , Ojeda Virginia , Moulick Kamalika , de Stanchina Elisa , Poirier John T. , Zauderer Marjorie , Rudin Charles M. , Karajannis Matthias A. , Hanemann C. Oliver , Giancotti Filippo G.
Published: April 2023

Figure S4 related to Figure 4 shows that GDC-0980 reduces mTORC1 and PI3K signaling in Merlin-mutant Meso-33 cells and the MSK-LX19 PDX model, p27 levels are dramatically increased by combined MLN4914 and GDC-0980 therapy, and that the treatments in Figure 4 were well-tolerated.
Supplementary Figure S4 from Selective Inhibition of ADAM28 Suppresses Lung Carcinoma Cell Growth and Metastasis
Authors: Mochizuki Satsuki , Shimoda Masayuki , Abe Hitoshi , Miyamae Yuka , Kuramoto Junko , Aramaki-Hattori Noriko , Ishii Ken , Ueno Hideki , Miyakoshi Akira , Kojoh Kanehisa , Okada Yasunori
Published: April 2023

Supplementary Figure S4 shows changes in body weight, results of organ weights and histology of mice treated with control mouse IgG or antibody 211-12 at 20 mg/kg body weight five times once a week.
Fig S2 from CD3-Bispecific Antibody Therapy Turns Solid Tumors into Inflammatory Sites but Does Not Install Protective Memory
Authors: Benonisson Hreinn , Altıntaş Işıl , Sluijter Marjolein , Verploegen Sandra , Labrijn Aran F. , Schuurhuis Danita H. , Houtkamp Mischa A. , Verbeek J. Sjef , Schuurman Janine , van Hall Thorbald
Published: April 2023

In vitro activation by bsAb of T cells
Supp. Methods from Exportin 1 Inhibition Induces Nerve Growth Factor Receptor Expression to Inhibit the NF-κB Pathway in Preclinical Models of Pediatric High-Grade Glioma
Authors: DeSisto John A. , Flannery Patrick , Lemma Rakeb , Pathak Amrita , Mestnik Shelby , Philips Natalie , Bales Natalie J. , Kashyap Trinayan , Moroze Erin , Venkataraman Sujatha , Kung Andrew L. , Carter Bruce D. , Landesman Yosef , Vibhakar Rajeev , Green Adam L.
Published: April 2023

Supplemental Methods
Supplemental Figures S1-S10 from Histone Deacetylase Inhibitors Synergize with Catalytic Inhibitors of EZH2 to Exhibit Antitumor Activity in Small Cell Carcinoma of the Ovary, Hypercalcemic Type
Authors: Wang Yemin , Chen Shary Yuting , Colborne Shane , Lambert Galen , Shin Chae Young , Santos Nancy Dos , Orlando Krystal A. , Lang Jessica D. , Hendricks William P.D. , Bally Marcel B. , Karnezis Anthony N. , Hass Ralf , Underhill T. Michael , Morin Gregg B. , Trent Jeffrey M. , Weissman Bernard E. , Huntsman David G.
Published: April 2023

Fig.S1 shows that SCCOHT cells are sensitive to HDAC inhibition. Fig. S2 shows that SCCOHT cells are sensitive to HDAC inhibition or depletion. Fig.S3 shows that SMARCA4/A2 dual deficiency is not associated with hypersensitivity to HDAC inhibitors in lung and pancreatic cancer cell lines. Fig.S4 shows that pan-HDAC inhibitors induce cell morphology changes in SCCOHT cells. Fig.S5 shows that SMARCA2 activation is partially required for the hypersensitivity of SCCOHT cells to HDAC inhibition. Fig. S6 shows the effect of quisinostat on mouse body weights in BIN67 mouse xenograft models. Fig.S7 shows the synergistic effects between HDAC inhibitors and EZH2 inhibitors in SWI/SNF deficiency-driven tumor cells. Fig. S8 shows that depletion of HDAC2 increased sensitivity of BIN67 cells to EPZ-6438 treatment. Fig.S9 shows the synergistic effects between HDAC inhibitors and EZH2 inhibitors in SCCOHT cells. Fig.S10 shows the effect of combined treatment of EPZ-6438 and quisinostat on mouse body weight and survival.
Supplementary Methods from Targeting Protein Translation by Rocaglamide and Didesmethylrocaglamide to Treat MPNST and Other Sarcomas
Authors: Chang Long-Sheng , Oblinger Janet L. , Burns Sarah S. , Huang Jie , Anderson Larry W. , Hollingshead Melinda G. , Shen Rulong , Pan Li , Agarwal Garima , Ren Yulin , Roberts Ryan D. , O'Keefe Barry R. , Kinghorn A. Douglas , Collins Jerry M.
Published: April 2023

Supplementary Methods
Supplementary Data from Concurrent Targeting of Potential Cancer Stem Cells Regulating Pathways Sensitizes Lung Adenocarcinoma to Standard Chemotherapy
Authors: Shibata Masahiro , Ooki Akira , Inokawa Yoshikuni , Sadhukhan Pritam , Ugurlu M. Talha , Izumchenko Evgeny , Munari Enrico , Bogina Giuseppe , Rudin Charles M. , Gabrielson Edward , Singh Anju , Hoque Mohammad O.
Published: April 2023

This is a file of "Supplementary Data".
Supplementary Figures from Synergism between ATM and PARP1 Inhibition Involves DNA Damage and Abrogating the G2 DNA Damage Checkpoint
Authors: Mak Joyce P.Y. , Ma Hoi Tang , Poon Randy Y.C.
Published: April 2023

Figure S1. Synthetic lethality between ATM loss and PARP1 inhibition. Figure S2. Synergism between inhibitors of ATM and PARP1 occurs in multiple cell lines and with different inhibitors. Figure S3. Co-inhibition of ATM and PARP1 prevents mitotic entry. Figure S4. Inhibitors of ATR, CHK1/2, and WEE1 do not act synergistically with PARPi. Figure S5. ATMi does not bypass the IR-induced DNA damage checkpoint. Figure S6. Inhibition of ATM increases cellular PARylation. Figure S7. Disruption of PARP1 with CRISPR-Cas9. Figure S8. Ablation of PARP1 promotes sensitivity to ATMi in HeLa cells.
Supplementary Table S3 from Paternally Expressed Gene 10 (PEG10) Promotes Growth, Invasion, and Survival of Bladder Cancer
Authors: Kawai Yoshihisa , Imada Kenjiro , Akamatsu Shusuke , Zhang Fan , Seiler Roland , Hayashi Tetsutaro , Leong Jeffrey , Beraldi Eliana , Saxena Neetu , Kretschmer Alexander , Oo Htoo Zarni , Contreras-Sanz Alberto , Matsuyama Hideyasu , Lin Dong , Fazli Ladan , Collins Colin C. , Wyatt Alexander W. , Black Peter C. , Gleave Martin E.
Published: April 2023

siRNAs and plasmids used in this study
Table S2 from Characterization of 7A5: A Human CD137 (4-1BB) Receptor Binding Monoclonal Antibody with Differential Agonist Properties That Promotes Antitumor Immunity
Authors: Kotanides Helen , Sattler Rose Marie , Lebron Maria B. , Carpenito Carmine , Shen Juqun , Li Jingxing , Surguladze David , Haidar Jaafar N. , Burns Colleen , Shen Leyi , Inigo Ivan , Pennello Anthony L. , Forest Amelie , Chen Xinlei , Chin Darin , Sonyi Andreas , Topper Michael , Boucher Lauren , Sharma Prachi , Zhang Yiwei , Burtrum Douglas , Novosiadly Ruslan D. , Ludwig Dale L. , Plowman Gregory D. , Kalos Michael
Published: April 2023

Table S2 shows human immune effector ADCC and CDC activity EC50 (nM)
Supplementary Figure 4 from High Tumor Mutational Burden Correlates with Longer Survival in Immunotherapy-Naïve Patients with Diverse Cancers
Authors: Riviere Paul , Goodman Aaron M. , Okamura Ryosuke , Barkauskas Donald A. , Whitchurch Theresa J. , Lee Suzanna , Khalid Noor , Collier Rachel , Mareboina Manvita , Frampton Garrett M. , Fabrizio David , Sharabi Andrew B. , Kato Shumei , Kurzrock Razelle
Published: April 2023

Supplementary Figure 4
Figure S6 from Characterization of 7A5: A Human CD137 (4-1BB) Receptor Binding Monoclonal Antibody with Differential Agonist Properties That Promotes Antitumor Immunity
Authors: Kotanides Helen , Sattler Rose Marie , Lebron Maria B. , Carpenito Carmine , Shen Juqun , Li Jingxing , Surguladze David , Haidar Jaafar N. , Burns Colleen , Shen Leyi , Inigo Ivan , Pennello Anthony L. , Forest Amelie , Chen Xinlei , Chin Darin , Sonyi Andreas , Topper Michael , Boucher Lauren , Sharma Prachi , Zhang Yiwei , Burtrum Douglas , Novosiadly Ruslan D. , Ludwig Dale L. , Plowman Gregory D. , Kalos Michael
Published: April 2023

Figure S6 shows antitumor efficacy of combination therapy in the NCI-H292 NSCLC tumor xenograft model
Figure S2 from Characterization of 7A5: A Human CD137 (4-1BB) Receptor Binding Monoclonal Antibody with Differential Agonist Properties That Promotes Antitumor Immunity
Authors: Kotanides Helen , Sattler Rose Marie , Lebron Maria B. , Carpenito Carmine , Shen Juqun , Li Jingxing , Surguladze David , Haidar Jaafar N. , Burns Colleen , Shen Leyi , Inigo Ivan , Pennello Anthony L. , Forest Amelie , Chen Xinlei , Chin Darin , Sonyi Andreas , Topper Michael , Boucher Lauren , Sharma Prachi , Zhang Yiwei , Burtrum Douglas , Novosiadly Ruslan D. , Ludwig Dale L. , Plowman Gregory D. , Kalos Michael
Published: April 2023

Figure S2 shows the species cross-reactivity of 7A5 antibody
Table S3 from Development of AO-176, a Next-Generation Humanized Anti-CD47 Antibody with Novel Anticancer Properties and Negligible Red Blood Cell Binding
Authors: Puro Robyn J. , Bouchlaka Myriam N. , Hiebsch Ronald R. , Capoccia Benjamin J. , Donio Michael J. , Manning Pamela T. , Frazier William A. , Karr Robert W. , Pereira Daniel S.
Published: April 2023

Table S3 is a summary of AO-176 mediated phagocytosis of solid and hematologic tumor cells
Figure S1 from Site-Specific PEGylation of Anti-Mesothelin Recombinant Immunotoxins Increases Half-life and Antitumor Activity
Authors: Zheng Zeliang , Okada Ryuhei , Kobayashi Hisataka , Nagaya Tadanobu , Wei Junxia , Zhou Qi , Lee Fred , Bera Tapan K. , Gao Yun , Kuhlman William , Tai Chin-Hsien , Pastan Ira
Published: April 2023

Cell Killing Activities of control RIT
Figure S2 from An Orally Available Tubulin Inhibitor, VERU-111, Suppresses Triple-Negative Breast Cancer Tumor Growth and Metastasis and Bypasses Taxane Resistance
Authors: Deng Shanshan , Krutilina Raisa I. , Wang Qinghui , Lin Zongtao , Parke Deanna N. , Playa Hilaire C. , Chen Hao , Miller Duane D. , Seagroves Tiffany N. , Li Wei
Published: April 2023

Figure S2 shows that images of the effects of VERU-111, paclitaxel and colchicine on inhibition of TNBC cell wound healing at a concentration of 16 nM. Representative images show that VERU-111 inhibits wound closure in MDA-MB-231 (upper panel) and MDA-MB-468 cells (lower panel).
Tables S1-3 and Figures S1-S8 from A Novel HER2-targeted Antibody–drug Conjugate Offers the Possibility of Clinical Dosing at Trastuzumab-equivalent Exposure Levels
Authors: Barfield Robyn M. , Kim Yun Cheol , Chuprakov Stepan , Zhang Fangjiu , Bauzon Maxine , Ogunkoya Ayodele O. , Yeo Dominick , Hickle Colin , Pegram Mark D. , Rabuka David , Drake Penelope M.
Published: April 2023

Contains 3 tables and 8 figures with legends.
Supplementary Table 1 from A Precision Medicine Drug Discovery Pipeline Identifies Combined CDK2 and 9 Inhibition as a Novel Therapeutic Strategy in Colorectal Cancer
Authors: Somarelli Jason A. , Roghani Roham Salman , Moghaddam Ali Sanjari , Thomas Beatrice C. , Rupprecht Gabrielle , Ware Kathryn E. , Altunel Erdem , Mantyh John B. , Kim So Young , McCall Shannon J. , Shen Xiling , Mantyh Christopher R. , Hsu David S.
Published: April 2023

Patient demographic are described in supplementary Table 1
Figure S1 from Circulating Tumor Cells and Biomarker Modulation with Olaratumab Monotherapy Followed by Olaratumab plus Doxorubicin: Phase Ib Study in Patients with Soft-Tissue Sarcoma
Authors: Martín-Broto Javier , Pousa Antonio López , Brohl Andrew S. , Van Tine Brian A. , Powers Benjamin , Stacchiotti Silvia , Blay Jean-Yves , Hu James S. , Oakley Gerard J. , Wang Hong , Szpurka Anna M. , Levy Donna E. , Mo Gary , Ceccarelli Matteo , Jones Robin L.
Published: April 2023

Study Design.
Figure S4 from The Indenoisoquinoline LMP517: A Novel Antitumor Agent Targeting both TOP1 and TOP2
Authors: Marzi Laetitia , Sun Yilun , Huang Shar-yin N. , James Amy , Difilippantonio Simone , Pommier Yves
Published: April 2023

Ku70 copy number and APLF expression are determinants of response to LMP517
Figure S1 from The Indenoisoquinoline LMP517: A Novel Antitumor Agent Targeting both TOP1 and TOP2
Authors: Marzi Laetitia , Sun Yilun , Huang Shar-yin N. , James Amy , Difilippantonio Simone , Pommier Yves
Published: April 2023

LMP517 induces marginal body weight loss in mice
Supplementary Figure 4 from The Role of Specific ATP-Binding Cassette Transporters in the Acquired Resistance to Pyrrolobenzodiazepine Dimer–Containing Antibody–Drug Conjugates
Authors: Corbett Simon , Huang Shiran , Zammarchi Francesca , Howard Philip W. , van Berkel Patrick H. , Hartley John A.
Published: April 2023

Supplementary Figure 4. ABCG2 transporter siRNA immunoblots in NCI-N87 resistant cells. A. Representative western blot for ABCG2 siRNA construct 1, 2, 3 or combination after 72 hours in NCI-N87 ADC resistant cell line. B. Representative western blot for ABCG2 siRNA construct 1, 2, 3 or combination after 72 hours in NCI-N87 PBD resistant cell line.
Table S1 from BRCA1/MAD2L1 Deficiency Disrupts the Spindle Assembly Checkpoint to Confer Vinorelbine Resistance in Mesothelioma
Authors: Busacca Sara , O'Regan Laura , Singh Anita , Sharkey Annabel J. , Dawson Alan G. , Dzialo Joanna , Parsons Aimee , Kumar Neelam , Schunselaar Laurel M. , Guppy Naomi , Nakas Apostolos , Sheaff Michael , Mansfield Aaron S. , Janes Sam M. , Baas Paul , Fry Andrew M. , Fennell Dean A.
Published: April 2023

Western blots quantification
Figure S5 from BRCA1/MAD2L1 Deficiency Disrupts the Spindle Assembly Checkpoint to Confer Vinorelbine Resistance in Mesothelioma
Authors: Busacca Sara , O'Regan Laura , Singh Anita , Sharkey Annabel J. , Dawson Alan G. , Dzialo Joanna , Parsons Aimee , Kumar Neelam , Schunselaar Laurel M. , Guppy Naomi , Nakas Apostolos , Sheaff Michael , Mansfield Aaron S. , Janes Sam M. , Baas Paul , Fry Andrew M. , Fennell Dean A.
Published: April 2023

Prognostic effect of MAD2L1 in second line cohort. Kaplan Meier curve for overall survival (OS) in patients treated with vinorelbine second line (n=3) stratified according to MAD2L1 expression
Figure S6 from Rapid Resistance of FGFR-driven Gastric Cancers to Regorafenib and Targeted FGFR Inhibitors can be Overcome by Parallel Inhibition of MEK
Authors: Lau David K. , Luk Ian Y. , Jenkins Laura J. , Martin Andrew , Williams David S. , Schoffer Kael L. , Chionh Fiona , Buchert Michael , Sjoquist Katrin , Boussioutas Alex , Hayes Sarah A. , Ernst Matthias , Weickhardt Andrew J. , Pavlakis Nick , Tebbutt Niall C. , Mariadason John M.
Published: April 2023

Supplementary Figure 6
Supplementary Data from Small Molecule Inhibitors of TEAD Auto-palmitoylation Selectively Inhibit Proliferation and Tumor Growth of NF2-deficient Mesothelioma
Authors: Tang Tracy T. , Konradi Andrei W. , Feng Ying , Peng Xiao , Ma Mingyue , Li Jian , Yu Fa-Xing , Guan Kun-Liang , Post Leonard
Published: April 2023

Supplementary Materials and Methods, Supplementary Figures and Figure Legends
Supplementary Figures from The Dolaflexin-based Antibody–Drug Conjugate XMT-1536 Targets the Solid Tumor Lineage Antigen SLC34A2/NaPi2b
Authors: Bodyak Natalya D. , Mosher Rebecca , Yurkovetskiy Aleksandr V. , Yin Mao , Bu Charlie , Conlon Patrick R. , Demady Damon R. , DeVit Michael J. , Gumerov Dmitry R. , Gurijala Venu R. , Lee Winnie , McGillicuddy Dennis , Park Peter U. , Poling Laura L. , Protopova Marina , Qin LiuLiang , Stevenson Cheri A. , Ter-Ovanesyan Elena , Uttard Alex , Xiao Dongmei , Xu Jian , Xu Ling , Bergstrom Donald A. , Lowinger Timothy B.
Published: April 2023

Supplementary Figures
Supplementary Tables from NAP1051, a Lipoxin A4 Biomimetic Analogue, Demonstrates Antitumor Activity Against the Tumor Microenvironment
Authors: Dong Tiange , Dave Priyal , Yoo EunJeong , Ebright Brandon , Ahluwalia Kabir , Zhou Eugene , Asante Isaac , Salimova Malika , Pei Hua , Lin Tracey , Mead Andrew , Li Zeyang , Humayun Mark , Petasis Nicos A. , Epstein Alan L. , Louie Stan G.
Published: April 2023

Table S1 lists flow cytometry antibodies and panel design. Table S2 lists primers for RT-PCR analyses. Table S3 includes antibodies for immunohistochemistry and immunofluorescent staining.
Supplementary Data from Anti-Glypican-1 Antibody–drug Conjugate as Potential Therapy Against Tumor Cells and Tumor Vasculature for Glypican-1–Positive Cholangiocarcinoma
Authors: Yokota Keiichiro , Serada Satoshi , Tsujii Shigehiro , Toya Keisuke , Takahashi Tsuyoshi , Matsunaga Takashi , Fujimoto Minoru , Uemura Sunao , Namikawa Tsutomu , Murakami Ichiro , Kobayashi Shogo , Eguchi Hidetoshi , Doki Yuichiro , Hanazaki Kazuhiro , Naka Tetsuji
Published: April 2023

Supplementary Data
Supplementary Table 3 from ONC212 is a Novel Mitocan Acting Synergistically with Glycolysis Inhibition in Pancreatic Cancer
Authors: Ferrarini Isacco , Louie Anna , Zhou Lanlan , El-Deiry Wafik S.
Published: April 2023

Supplementary Table S3: blood chemistry results of mice treated with ONC212 or the combination of ONC212 and 2-DG
Supplementary Methods from SAM-Competitive PRMT5 Inhibitor PF-06939999 Demonstrates Antitumor Activity in Splicing Dysregulated NSCLC with Decreased Liability of Drug Resistance
Authors: Jensen-Pergakes Kristen , Tatlock John , Maegley Karen A. , McAlpine Indrawan J. , McTigue Michele , Xie Tao , Dillon Christopher P. , Wang Yuli , Yamazaki Shinji , Spiegel Noah , Shi Manli , Nemeth Amy , Miller Natalie , Hendrickson Eleanore , Lam Hieu , Sherrill John , Chung Chi-Yeh , McMillan Elizabeth A. , Bryant Shannon Karlicek , Palde Prakash , Braganza John , Brooun Alexei , Deng Ya-Li , Goshtasbi Vesta , Kephart Susan E. , Kumpf Robert A. , Liu Wei , Patman Ryan L. , Rui Eugene , Scales Stephanie , Tran-Dube Michelle , Wang Fen , Wythes Martin , Paul Thomas A.
Published: April 2023

Supplemental Methods